alexa How Can Modeling And Simulation Optimize The Clinical Development Of Adalimumab Biosimilar Candidates?
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Bernardo Miguel-Lillo and Daniel Röeshammar
SGS Exprimo, Belgium
Posters & Accepted Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-027
Abstract
Generally, Pharmacokinetics (PK) trials for adalimumab biosimilar candidates are oversized as high variability is expected. Sample size /arm varies from 60 to 108 subjects. An inadequate sample size could jeopardize the trial outcome. In this context, a population pharmacokinetic model of adalimumab in rheumatoid arthritis (RA) patients was used to obtain empirical Bayesian estimates (EBE) from in recent adalimumab biosimilar development. Consequently, EBEs of PK parameters for adalimumab EU- and US-approved formulations were implemented in the simulation software Simulo, and simulations of adalimumab PK were carried out at the dose proposed in the adalimumab product information monograph in RA of 40 mg subcutaneus (sc) injection. In addition, the effect of subject´s weight was implemented in the simulation software. These simulations were carried out to explore the effects of the simulated adalimumab serum concentrations on the PK pivotal study design in terms of sample size, in order to estimate the PK parameters required to address PK similarity between adalimumab biosimilar candidates and adalimumab. Then the likelihood of simulated study design scenarios was evaluated following the regulatory exercise to demonstrate PK similarity. The influence of neutralizing anti-adalimumab antibodies (AAA+) was also explored. The population PK model was qualified using different approaches, including comparison of the predicted versus observed adalimumab serum concentrations and PK parameters validation. They demonstrated good accuracy in capturing the adalimumab PK in the population. Therefore the existing model was considered well suited for this simulation task. Power analysis of the results for PK similarity tests showed that larger trials (+150 subjects) did not improve significantly the probability to obtain bioequivalence when compared with smaller trials. A maximum difference of 15% in AAA+ could decrease the chance to obtain successful results for all pairwise comparisons. Model-based simulations approach, incorporating available information of adalimumab, yield a reduced sample size (40-60% decreased), compared to traditional methods. Overall, this can be considered as the optimum rationale for supporting the design for a PK pivotal study of adalimumab biosimilar candidate to address PK similarity.
Biography

Bernardo Miguel-Lillo has his expertise in evaluation and optimizing study designs, especially in the field of Oncology. He has applied model and simulation after years of experience in research, evaluation and analyzing pharmacokinetic and pharmacodynamic data in pharmaceutical industry. His main focus of interest is in the contribution of pharmacometrics in the decision making process for drug development.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version